Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation

Oncogene

Volumn 35, Issue 9, 2016, Pages 1198-1205

  Pazarentzos, E ^a,b   Giannikopoulos, P ^c   Hrustanovic, G ^a,b   St John, J ^c   Olivas, V R ^a   Gubens, M A ^a,b   Balassanian, R ^a   Weissman, J ^a,d   Polkinghorn, W ^c   Bivona, T G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Driver Group   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERLOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE C BETA; PHOSPHATIDYLINOSITOL 3 KINASE P110BETA ISOFORM; UNCLASSIFIED DRUG; ISOPROTEIN; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CB PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; PYRIMIDINONE DERIVATIVE; TGX 221;

ADULT; ARTICLE; CARCINOGENESIS; CELL ENGINEERING; CELL GROWTH; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; ENZYME INHIBITION; EXOME; FEMALE; GLIOBLASTOMA; GROWTH INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; MALE; MELANOMA; MUTANT; NON SMALL CELL LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THYROID CARCINOMA; TUMOR BIOPSY; TUMOR PROMOTION; 3T3 CELL LINE; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG EFFECTS; GENETICS; MOUSE; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MICE; MORPHOLINES; MUTATION; NIH 3T3 CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN ISOFORMS; PTEN PHOSPHOHYDROLASE; PYRIMIDINONES; SIGNAL TRANSDUCTION;

EID: 84959576665     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.173     Document Type: Article

References (27)

1. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014; 4: 64.
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619.
3. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4: 127-150.
4. Bauer TM, Patel MR, Infante JR. Targeting PI3 kinase in cancer. Pharmacol Ther 2015; 146C: 53-60.
5. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
6. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 2007; 32: 342-349.
7. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005; 102: 802-807.
8. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10: 558-565.
9. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94: 455-459.
10. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11: 289-301.
11. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008; 27: 5527-5541.
12. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011; 17: 3812-3821.
13. Kosaka T, Yamaki E, Mogi A, Kuwano H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011; 2011: 165214.
14. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17: 5530-5537.
15. Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A. Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol 2013; 4: 15.
16. Schroeder MP, Gonzalez-Perez A, Lopez-Bigas N. Visualizing multidimensional cancer genomics data. Genome Med 2013; 5: 9.
17. Deuker MM, Durban VM, Phillips WA, McMahon M. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov 2014; 5: 143-153.
18. Charles RP, Silva J, Iezza G, Phillips WA, McMahon M. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res 2014; 12: 979-986.
19. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454: 776-779.
20. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-514.
21. Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T et al. Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett 2011; 2: 774-779.
22. Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 2008; 74: 793-806.
23. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69: 3256-3261.
24. Lammers PE, Lovly CM, Horn L. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw 2014; 12: 6-11.
25. Dbouk HA, Khalil BD, Wu H, Shymanets A, Nurnberg B, Backer JM. Characterization of a tumor-associated activating mutation of the p110beta PI 3-kinase. PloS One 2013; 8: e63833.
26. Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci USA 2014; 111: E748-E757.
27. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-1079.